Iktos announced that Kissei Pharmaceutical Co., Ltd. has introduced Makya, Iktos Software as a Service Platform for AI-driven drug discovery. This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development. Iktos's AI technology, based on deep generative models and on a comprehensive data-driven chemical structure generation technology, helps to bring new insights and directions into the molecular discovery process and foster medicinal chemist's productivity and acceleration of the identification of new drug candidates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,145 JPY | +1.45% |
|
-0.63% | +1.78% |
Jun. 10 | Kissei Pharmaceutical Licenses Linzagolix to JW Pharmaceutical for Korean Market | MT |
Jun. 10 | Kissei Pharmaceutical Co., Ltd. Enters into License Agreement with Jw Pharmaceutical Corporation | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.78% | 884M | |
+15.93% | 9.25B | |
+42.06% | 4.45B | |
-22.01% | 4.43B | |
+8.28% | 4.03B | |
+11.22% | 2.24B | |
-26.61% | 2.18B | |
+11.64% | 2.02B | |
-42.69% | 1.79B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- 4547 Stock
- News Kissei Pharmaceutical Co., Ltd.
- Kissei Pharmaceutical Co., Ltd. Introduces Iktos AI Drug Discovery System